Complex R&D projects
We manage proof-of-concept R&D to support strategic portfolio decisions — conjugates, novel vectors, proteins and oligonucleotides — from feasibility to partner-ready.
Project partner · go/no-go, years before launch
Clear answers for complex APIs.
Brick 42 partners with generic pharmaceutical companies on complex APIs four to six years from launch. We answer the difficult go/no-go questions early — feasibility, cost at scale, the route to a filing, exclusivity — because the earlier they are answered, the more likely you choose the right products, and the more likely they succeed.
The first answerHow it comes
| Is the route feasible at scale? | a go/no-go, with assumptions |
| What will a kilo cost at launch? | a range, with the working |
| What stands between us and a filing? | the gaps, by region |
| Can we hold exclusivity? | territory by territory |
Free and confidential. Replies within two working days.
Project partner, not a catalogue
Go/no-go, years before launch
SwissMedic-authorised to trade
EU / CH funded research
TRANSBORO · Interreg partner
What we answer
The questions that come first.
A generic programme is decided years before a purchase order exists. These are the early questions — and every page here leads with its answer, with the working shown.
| Is the route feasible at commercial scale? | a go/no-go, with the assumptions |
| What will a kilo cost when the market opens? | a range, with the working shown |
| What stands between us and a filing, by region? | the gaps, listed early |
| Can we hold exclusivity in our territory? | territory by territory, in writing |
| What are the supply and route risks? | named, with mitigations |
| When does the market actually open? | a timeline, not a slogan |
Where we work
Complex APIs, by class.
We work where the early questions are hardest — the classes where answering them years before launch decides whether the programme succeeds.
The first brief
What an early answer settles.
The first module of the Decision Support tool: the go/no-go dimensions a programme needs before it commits. At launch this panel is structure only — what is not evidenced is never implied.
The first briefstructure only
| Question | What you get |
|---|---|
| Route feasibility | a go/no-go, with assumptions |
| Cost at scale | a range, with the working |
| Filing path | the gaps, by region |
| Exclusivity | territory by territory |
| Supply & route risk | named, with mitigations |
| Market timing | a timeline, not a slogan |
Structure only — live answers ship with the tool. What is not evidenced is never implied.
Evidence
The work behind the answers.
A small project partner, deliberately agile — engaged in funded research and flexible enough to move when a generic market opens.
TRANSBORO
An Interreg VI-A Italy–Switzerland (2021–2027) project in Boron Neutron Capture Therapy, with Exeris Bio SA, the University of Eastern Piedmont and the University of Pavia. Co-funded by Interreg, the EU and Canton Ticino.
Partnerships & investment
A joint venture with Exeris SA — exerisbio SA — and an investment in protein research: the collaborations behind the pipeline and the route to new molecules.
Decision Support tool · Gate Brief
Start with a CAS. Leave with a decision.
A free, anonymous brief on any API — recommendation first, evidence attached, and the reverse timeline to an EU launch made explicit. Built to save a portfolio meeting, not to sell in it.
Open the Gate Brief- AccessFree · confidential · anonymous
- InputCAS number or API name
- ReturnsAdvance · hold · monitor · stop
- EvidenceSource, date, confidence, caveat
Insights
What we're watching.
Research notes and regulatory intelligence, migrated from the Brick 42 archive. Full articles move into this section as they are re-voiced.
BNCT
Boron: the new carbon in drug discovery
featured
Market
BNCT market hits $3.1 billion — a new era for precision oncology
featured
Clinical
Japan leads with clinical BNCT for cancer
featured
Manufacturing
On-shore high-potency pharma manufacturing in the US and EU
featured
Contact
Ask the question.
Tell us the API and the stage. You'll get an answer — with the assumptions stated — within two working days.